A detailed history of Fred Alger Management, LLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Fred Alger Management, LLC holds 182,765 shares of IOVA stock, worth $1.41 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
182,765
Holding current value
$1.41 Million
% of portfolio
0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$7.59 - $17.47 $1.39 Million - $3.19 Million
182,765 New
182,765 $2.71 Million
Q1 2021

May 17, 2021

SELL
$28.67 - $52.59 $539,626 - $989,848
-18,822 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$28.04 - $50.26 $350,079 - $627,496
-12,485 Reduced 39.88%
18,822 $873,000
Q3 2020

Nov 13, 2020

SELL
$27.75 - $36.3 $1.01 Million - $1.32 Million
-36,295 Reduced 53.69%
31,307 $1.03 Million
Q2 2020

Aug 14, 2020

BUY
$27.21 - $41.0 $1.21 Million - $1.83 Million
44,602 Added 193.92%
67,602 $1.86 Million
Q1 2020

May 15, 2020

SELL
$19.54 - $38.85 $429,880 - $854,700
-22,000 Reduced 48.89%
23,000 $689,000
Q4 2019

Feb 14, 2020

SELL
$17.95 - $29.41 $771,850 - $1.26 Million
-43,000 Reduced 48.86%
45,000 $1.25 Million
Q3 2019

Nov 14, 2019

SELL
$17.99 - $26.0 $305,830 - $442,000
-17,000 Reduced 16.19%
88,000 $1.6 Million
Q2 2019

Aug 14, 2019

BUY
$9.78 - $24.52 $97,800 - $245,200
10,000 Added 10.53%
105,000 $2.58 Million
Q1 2019

May 14, 2019

BUY
$8.41 - $11.26 $798,950 - $1.07 Million
95,000 New
95,000 $903,000
Q3 2018

Nov 14, 2018

SELL
$11.25 - $17.7 $90,000 - $141,600
-8,000 Closed
0 $0
Q2 2018

Jul 19, 2018

BUY
$12.45 - $16.95 $99,600 - $135,600
8,000 New
8,000 $102,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.22B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Fred Alger Management, LLC Portfolio

Follow Fred Alger Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fred Alger Management, LLC with notifications on news.